Hibsago (bepirovirsen)

Where it stands

Hibsago (bepirovirsen) is approved in the US. The FDA approved it on 2026-10-20 under NDA221276, with Glaxosmithkline Llc as the company. The FDA's announcement describes it as a new medicine, and the dosage form is an injection.

The records leave the indication and therapeutic area blank. This analysis therefore does not describe the approved patient population, dosing or clinical benefit. Anyone relying on this product should check the approved prescribing information and the FDA approval letter for those details.

The records contain no CHMP opinion date, so they show no EU regulatory step for this product. The only milestone recorded is the US approval.

Regulatory pathway and designations

The product was reviewed as a new drug application (NDA) and carries two designations: New molecular entity and Priority review. New molecular entity means the active ingredient had not previously been approved by the FDA. Priority review is a review-speed designation. Under PDUFA it sets a shorter target review clock than standard review, and the FDA grants it to applications for products that may offer a significant improvement in the safety or effectiveness of treating, diagnosing or preventing a serious condition.

The records do not give the submission date, the PDUFA goal date or the number of review cycles, so I cannot say how the approval compared with its target date. They also do not say whether other expedited programs, such as Breakthrough Therapy or Fast Track, applied, or whether approval was full or accelerated. Only the designations listed above are confirmed.

Safety and pharmacovigilance

The records contain no safety information for Hibsago. They list no boxed warning, REMS, contraindications, adverse-event data or postmarketing requirements, so no safety conclusions can be drawn here.

What to watch

The first step is to read the approved label and approval package once available. They will set out the indication, the dosing and any postmarketing commitments or risk-management measures, none of which are in the records.

Other points are not covered by the records, so no developments are assumed. These include any EU or other ex-US filing and CHMP timing, the US launch, and any early post-approval safety communications. Readers should track official FDA and company sources for these.